BioSpace News Archive

Asensus Surgical, Inc. announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 23,809,524 shares of its common stock and warrants to purchase 23,809,524 shares of common stock in a registered direct offering.

NS Pharma, Inc. announced today the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy Designation to NS-089/NCNP-02, an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 44 skipping therapy.

Prometheus Laboratories Inc. announced the launch of PredictrPK ADA, a precision-guided dosing test for adult Crohn’s disease (CD) patients receiving ADA treatment.

Celularity Inc. today announced that it has entered into a definitive agreement with a single, healthcare-focused institutional investor for the purchase and sale of 8,571,428 shares of its Class A common stock.

CUTERA, INC. (“Cutera” or the “Company”) (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today announced that Taylor Harris has been appointed Chief Executive Officer, effective August 7, 2023.

Headlands Research, a leading multinational network of clinical trial sites, today announced the acquisition of AMCR Institute, which has been in operation for more than 20 years.

OKYO Pharma Limited (Nasdaq: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, is pleased to announce that it has appointed William A. Clementi, Pharm.D., FCP as Chief Operating Officer.

DELFI Diagnostics, a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has exclusively licensed a new, highly accurate method for identifying somatic genomic alterations in cell-free DNA known as GEMINI, or GEnome-wide Mutational Incidence for Non Invasive detection of cancer.

MaaT Pharma (EURONEXT: MAAT – the “Company”) today provided a business update and reported its cash position as of June 30, 2023 and its revenues for the second quarter of 2023.

ReAlta Life Sciences, Inc., a company addressing life-threatening rare diseases through harnessing the power of the immune system, was pleased to welcome Congressman Robert C. “Bobby” Scott for an in-depth visit and tour of our Norfolk-based research and development facilities on July 24, 2023.